Attenuation of premature estrous behavior in postpartum beef cows synchronized to estrus using GnRH and PGF2alpha.
The efficacy of GnRH and PGF2alpha (7-day injection interval) for estrus synchronization is diminished by estrous expression before PGF2alpha (premature estrus; PE). Effects of modifications to GnRH-PGF2alpha protocols on the incidence of PE and other indicators of reproductive performance were evaluated. In Experiment 1, Angus-based crossbred cows (n=51) received 25 mg of PGF2alpha i.m. on Day 0. Animals were randomly assigned by parity and interval postpartum to receive GnRH 100 microg i.m. on either Day -7 or Day -6. Estrous detection and AI were conducted from Day -3 to Day 5. Treatment had no effect on the incidence of PE, estrous response, conception rate per AI or synchronized pregnancy rate (6- vs. 7-day interval; 8 vs. 15%; 92 vs. 93%; 77 vs. 76%; 71 vs. 70%, respectively). In Experiment 2, Angus cows (n=150) received GnRH 100 microg i.m. on Day -7 and 25 mg PGF2alpha i.m. on Day 0. Animals were randomly assigned by parity, interval postpartum, and body condition score to receive either no further treatment (Control) or 0.5 mg melengestrol acetate/hd/d from Day -7 to Day -1 (MGA). Estrous detection and AI were conducted from Day -2 to Day 7. Fewer (P < 0.05) MGA-treated cows were detected in PE (0%) compared to controls (7%). Treatment had no effect on estrous response or synchronized pregnancy rates (Control vs. MGA; 78 vs. 84%; 52 vs. 60%, respectively). Conception rate per AI of cows > or = 60 days postpartum were not affected by treatment (Control vs. MGA; 79 vs. 73%) however, control cows < 60 days postpartum tended (P < 0.10) to have lower conception rates per AI (39%) than did their MGA-treated counterparts (69%). In summary, 6- and 7-day GnRH-PGF2alpha injection intervals resulted in similar synchronized reproductive performance. Inclusion of MGA feeding between GnRH and PGF2alpha injections eliminated the occurrence of premature estrus and improved conception rate per AI of late-calving cows.
Dejarnette
J M
JM
Select Sires, Inc., Plain City, Ohio, USA. jmdejarnette@selectsires.com
Wallace
R W
RW
House
R B
RB
Salverson
R R
RR
Marshall
C E
CE
D000818:Animals; D002417:Cattle / Q000502:physiology*; D015237:Dinoprost / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004971:Estrus / Q000187:drug effects / Q000502:physiology*; D004973:Estrus Synchronization; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D007315:Insemination, Artificial / Q000662:veterinary; D016015:Logistic Models; D008297:Male; D008552:Melengestrol Acetate / Q000008:administration & dosage*; D049590:Postpartum Period; D011247:Pregnancy; D045167:Progesterone Congeners / Q000008:administration & dosage*; D011897:Random Allocation; D013997:Time Factors
D045167:Progesterone Congeners; D007987:Gonadotropin-Releasing Hormone; D008552:Melengestrol Acetate; D015237:Dinoprost